These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 20673029)

  • 1. Approaches to transfusion therapy and iron overload in patients with sickle cell disease: results of an international survey.
    Vichinsky EP; Ohene-Frempong K;
    Pediatr Hematol Oncol; 2011 Feb; 28(1):37-42. PubMed ID: 20673029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients.
    Koren A; Fink D; Admoni O; Tennenbaum-Rakover Y; Levin C
    Eur J Haematol; 2010 Jan; 84(1):72-8. PubMed ID: 19732137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
    Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease.
    Marsella M; Borgna-Pignatti C
    Hematol Oncol Clin North Am; 2014 Aug; 28(4):703-27, vi. PubMed ID: 25064709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic iron overload in children with sickle cell anemia on chronic transfusion therapy.
    Brown K; Subramony C; May W; Megason G; Liu H; Bishop P; Walker T; Nowicki MJ
    J Pediatr Hematol Oncol; 2009 May; 31(5):309-12. PubMed ID: 19415007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of high dose intravenous desferrioxamine for reduction of iron overload in sickle cell disease.
    Kalpatthi R; Peters B; Kane I; Holloman D; Rackoff E; Disco D; Jackson S; Laver JH; Abboud MR
    Pediatr Blood Cancer; 2010 Dec; 55(7):1338-42. PubMed ID: 20981690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload.
    Gattermann N
    Leuk Res; 2007 Dec; 31 Suppl 3():S10-5. PubMed ID: 18037413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention.
    Kwiatkowski JL; Cohen AR; Garro J; Alvarez O; Nagasubramanian R; Sarnaik S; Thompson A; Woods GM; Schultz W; Mortier N; Lane P; Mueller B; Yovetich N; Ware RE;
    Am J Hematol; 2012 Feb; 87(2):221-3. PubMed ID: 22120913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absence of cardiac siderosis by MRI T2* despite transfusion burden, hepatic and serum iron overload in Lebanese patients with sickle cell disease.
    Inati A; Musallam KM; Wood JC; Sheikh-Taha M; Daou L; Taher AT
    Eur J Haematol; 2009 Dec; 83(6):565-71. PubMed ID: 19737308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ferritin trends do not predict changes in total body iron in patients with transfusional iron overload.
    Puliyel M; Sposto R; Berdoukas VA; Hofstra TC; Nord A; Carson S; Wood J; Coates TD
    Am J Hematol; 2014 Apr; 89(4):391-4. PubMed ID: 24347294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Australian guidelines for the assessment of iron overload and iron chelation in transfusion-dependent thalassaemia major, sickle cell disease and other congenital anaemias.
    Ho PJ; Tay L; Lindeman R; Catley L; Bowden DK
    Intern Med J; 2011 Jul; 41(7):516-24. PubMed ID: 21615659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial.
    Vichinsky E; Pakbaz Z; Onyekwere O; Porter J; Swerdlow P; Coates T; Lane P; Files B; Mueller BU; Coïc L; Forni GL; Fischer R; Marks P; Rofail D; Abetz L; Baladi JF
    Acta Haematol; 2008; 119(3):133-41. PubMed ID: 18408362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consequences and management of iron overload in sickle cell disease.
    Porter J; Garbowski M
    Hematology Am Soc Hematol Educ Program; 2013; 2013():447-56. PubMed ID: 24319218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Iron overload in sickle cell anemia : a study of 94 patients].
    Hafsia R; Belakhal F; Ben Salah N; Gouider E; Elborgi W
    Tunis Med; 2011 Jun; 89(6):548-52. PubMed ID: 21681718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac iron overload in sickle-cell disease.
    Meloni A; Puliyel M; Pepe A; Berdoukas V; Coates TD; Wood JC
    Am J Hematol; 2014 Jul; 89(7):678-83. PubMed ID: 24664847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron overload in thalassaemia intermedia: reassessment of iron chelation strategies.
    Taher A; Hershko C; Cappellini MD
    Br J Haematol; 2009 Dec; 147(5):634-40. PubMed ID: 19681884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current approach to iron chelation in children.
    Aydinok Y; Kattamis A; Viprakasit V
    Br J Haematol; 2014 Jun; 165(6):745-55. PubMed ID: 24646011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transfusion and chelation practices in sickle cell disease: a regional perspective.
    Vichinsky EP; Ohene-Frempong K; Thein SL; Lobo CL; Inati A; Thompson AA; Smith-Whitley K; Kwiatkowski JL; Swerdlow PS; Porter JB; Marks PW
    Pediatr Hematol Oncol; 2011 Mar; 28(2):124-33. PubMed ID: 20673030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy.
    Leitch HA
    Leuk Res; 2007 Dec; 31 Suppl 3():S7-9. PubMed ID: 18037416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nontransferrin-bound iron in transfused patients with sickle cell disease.
    Inati A; Musallam KM; Cappellini MD; Duca L; Taher AT
    Int J Lab Hematol; 2011 Apr; 33(2):133-7. PubMed ID: 21382180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.